Biocon Biologics to Purchase Biosimilars Belongings from Viatris in $3.3 Billion Deal
Biocon Biologics will purchase Viatris’ world biosimilars enterprise, together with the corporate’s portfolio of in-licensed biosimilar belongings, in a transaction…